SAN FRANCISCO, November 6, 2022 (GLOBE NEWSWIRE) — i Rhythm Technologies Co., Ltd. (NASDAQ:IRTC), a leading cardiovascular diagnostic and digital healthcare solutions company focused on creating trusted solutions to detect, predict and prevent disease, today announced mSToPS researchpresented at the American Heart Association’s 2022 Science Session event.
Entitled “Cost-Effectiveness of AF Screening Using a 2-Week Patch Monitor: A mHealth Screening Study for Stroke Prevention,” the study evaluated the cost-effectiveness of screening for atrial fibrillation (AFib) with the Zio XT. it was done. The analysis found that systematic screening for AFib in at-risk populations using iRhythm Zio XT patches offers high value from a health economics perspective.
Over 3 years, individuals prescribed Zio XT were more likely than unmonitored individuals to undergo outpatient visits, including cardiologists, but were less likely to require emergency department visits or hospitalization. less likely. In patient-level projections, the Zio XT-prescribed group had slightly better overall and quality-adjusted survival (11.91 vs. 11.82 life years, 9.38 vs. 9.30 years). The study showed an incremental cost-effectiveness ratio (ICER) of $17,000. The ICER is well below the willingness-to-pay thresholds accepted by the United States and other healthcare systems. The authors concluded that screening for his AFib with Zio XT offers high value from a health economics perspective.
“The mSToPS is the first study to observe the benefits of AFib screening at 3 years. It is also the first study to be completed, said Matthew R. Reynolds, Ph.D., cardiac electrophysiologist at Lahey Hospital & Medical Center for Clinical Research and the BIM Institute.
mSToPS is a landmark direct participants randomized clinical trial combined with a prospective matched observational cohort study.Research published in Journal of the American Medical Association Conducted at the Scripps Research Translational Institute in partnership with Aetna and Janssen Pharmaceuticals in 2018, Zio XT-based screening has been associated with increased detection of atrial fibrillation, increased use of outpatient cardiology care, and increased use of stroke prevention therapy. found to be associated with increased initiation rates. . a Three-year follow-up analysis of mSToPS studieswas published in pro swan found, in 2021, that screening with Zio XT was associated with a lower incidence of clinical events and improved outcomes compared to a matched cohort.
“Together, these studies demonstrate that AFib screening in at-risk populations can lead to patient health outcomes, especially when combined with appropriate therapies such as stroke prevention, rhythm control, and risk factor modification. Medical Officer and Chief Scientific Officer of iRhythm. “These studies are not isolated and are based on strong evidence from randomized trials, including STROKE-STOP, EAST-AFNET 4 and more. This is why we launched Know Your Rhythm.®This is a risk-sharing program that partners with healthcare systems to assess undiagnosed atrial fibrillation and other arrhythmias and link this to evidence-based treatment initiation. ”
For more information on iRhythm, please visit: website.
About “Cost-Effectiveness of AF Screening by Two-Week Patch Monitor: mHealth Screening Study for Stroke Prevention”
Authors: Matthew R. Reynolds, MD; Amy B. Stein, Ph.D. Dr. Evangelos Hytopoulos. Xiaowu Sun, PhD. Dr. Stephen R. Steinhab.David J. Cohen, MD
The authors performed a health economics analysis of AFib screening using the Zio ambulatory ECG monitor using patient-level data from the mSToPS study. Clinical outcomes and costs from the payer’s perspective were obtained using Aetna’s claims data over his 3-year period from enrollment. Study group participants (average age 74, female 41%, CHA median)2DS2-VASC score 3) wore an average of 1.7 2-week ambulatory ECG monitors at an average cost of $601 per person. Over three years, individuals prescribed the Zio Patch Monitor were more likely than unmonitored individuals to have outpatient visits, including heart disease, but were less likely to require an emergency department visit or hospitalization. less likely. Three-year drug costs were similar between groups. Adjusted 3-year total costs including patch monitoring were slightly higher in the surveillance group (difference $1,170, 95% CI -1,315 to 3,657). Patient-level projections showed that the monitoring arm had slightly improved overall and quality-adjusted survival (11.91 vs. 11.82 life years, 9.38 vs. 9.30 QALYs) and slightly higher lifetime costs, resulting in an incremental cost-effectiveness ratio of $16,978. /QALY now. Obtained. Based on the lifetime predictions derived from the mSToPS study, the investigators conclude that AF screening using her Zio XT patch monitoring for 2 weeks offered high value in terms of health economics.
About iRhythm Technologies, Inc.
iRhythm is a leading digital healthcare company that creates trusted solutions to detect, predict and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heart beats into clinically actionable information. iRhythm’s vision is to bring better data, better insights and better health to everyone with a relentless focus on patient care.
Investor Information Contact:
Stephanie Zadkiewicz
(919) 452-5430
stephanie.zhadkevich@irhythmtech.com
iRhythm media contact:
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com
